Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1990 Dec;62(6):1042–1046. doi: 10.1038/bjc.1990.436

Paradoxical effects of 5-FU/folinic acid on lymphokine-activated killer (LAK) cell induction in patients with colorectal cancer.

H Onodera 1, S S Somers 1, P J Guillou 1
PMCID: PMC1971584  PMID: 2257211

Abstract

The effects of treatment with 5-FU/folinic acid on interleukin-2 related lymphocyte responses was investigated in 21 patients with advanced colorectal cancer. The treatment was not suppressive of IL-2 related lymphocyte responses. Furthermore, at certain time points in the treatment cycles the capacity to generate lymphokine-activated killer (LAK) cells from the peripheral blood mononuclear cells of these patients was significantly augmented above that observed prior to treatment. These results provide a logical basis for the design of regimens which combine two approaches, each of low individual therapeutic efficacy, to treat patients with advanced colorectal cancer in the hope of increasing clinical response rates.

Full text

PDF
1042

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ades E. W., McKemie C. R., 3rd, Wright S., Peacocke N., Pantazis C., Lockhart W. L., 3rd Chemotherapy subsequent to recombinant interleukin-2 immunotherapy: protocol for enhanced tumoricidal activity. Nat Immun Cell Growth Regul. 1987;6(5):260–268. [PubMed] [Google Scholar]
  2. Arbuck S. G. Overview of clinical trials using 5-fluorouracil and leucovorin for the treatment of colorectal cancer. Cancer. 1989 Mar 15;63(6 Suppl):1036–1044. doi: 10.1002/1097-0142(19890315)63:6+<1036::aid-cncr2820631309>3.0.co;2-k. [DOI] [PubMed] [Google Scholar]
  3. Arinaga S., Akiyoshi T., Tsuji H. Augmentation of the generation of cell-mediated cytotoxicity after a single dose of adriamycin in cancer patients. Cancer Res. 1986 Aug;46(8):4213–4216. [PubMed] [Google Scholar]
  4. Boldt D. H., Mills B. J., Gemlo B. T., Holden H., Mier J., Paietta E., McMannis J. D., Escobedo L. V., Sniecinski I., Rayner A. A. Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans. Cancer Res. 1988 Aug 1;48(15):4409–4416. [PubMed] [Google Scholar]
  5. Borst J., van de Griend R. J., van Oostveen J. W., Ang S. L., Melief C. J., Seidman J. G., Bolhuis R. L. A T-cell receptor gamma/CD3 complex found on cloned functional lymphocytes. Nature. 1987 Feb 19;325(6106):683–688. doi: 10.1038/325683a0. [DOI] [PubMed] [Google Scholar]
  6. Doroshow J. H., Bertrand M., Newman E., Multhauf P., Leong L., Blayney D., Goldberg D., Margolin K., Carr B., Akman S. Preliminary analysis of a randomized comparison of 5-fluorouracil versus 5-fluorouracil and high-dose continuous-infusion folinic acid in disseminated colorectal cancer. NCI Monogr. 1987;(5):171–174. [PubMed] [Google Scholar]
  7. Eggermont A. M., Sugarbaker P. H. Efficacy of chemoimmunotherapy with cyclophosphamide, interleukin-2 and lymphokine activated killer cells in an intraperitoneal murine tumour model. Br J Cancer. 1988 Oct;58(4):410–414. doi: 10.1038/bjc.1988.231. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Erlichman C., Fine S., Wong A., Elhakim T. A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol. 1988 Mar;6(3):469–475. doi: 10.1200/JCO.1988.6.3.469. [DOI] [PubMed] [Google Scholar]
  9. Gillis S., Ferm M. M., Ou W., Smith K. A. T cell growth factor: parameters of production and a quantitative microassay for activity. J Immunol. 1978 Jun;120(6):2027–2032. [PubMed] [Google Scholar]
  10. Guillou P. J., Sedman P. C., Ramsden C. W. Inhibition of lymphokine-activated killer cell generation by cultured tumor cell lines in vitro. Cancer Immunol Immunother. 1989;28(1):43–53. doi: 10.1007/BF00205800. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Hamblin T. J., Inzani V., Sadullah S., Stevenson F. K., Williamson P., van der Plas J., Palmer P., Franks C. R. A phase-II trial of recombinant interleukin-2 and 5-FU chemotherapy in patients with metastatic colorectal carcinoma. Cancer Treat Rev. 1989 Jun;16 (Suppl A):163–167. doi: 10.1016/0305-7372(89)90037-6. [DOI] [PubMed] [Google Scholar]
  12. Kempf R. A., Mitchell M. S. Effects of chemotherapeutic agents on the immune response. I. Cancer Invest. 1984;2(6):459–466. doi: 10.3109/07357908409048519. [DOI] [PubMed] [Google Scholar]
  13. Kerr D. J. 5-Fluorouracil and folinic acid: interesting biochemistry or effective treatment? Br J Cancer. 1989 Dec;60(6):807–808. doi: 10.1038/bjc.1989.370. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Kiyohara T., Taniguchi K., Kubota S., Koga S., Sakuragi T., Saitoh Y. Induction of lymphokine-activated killer-like cells by cancer chemotherapy. J Exp Med. 1988 Dec 1;168(6):2355–2360. doi: 10.1084/jem.168.6.2355. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Koide J., Rivas A., Engleman E. G. Natural killer (NK)-like cytotoxic activity of allospecific T cell receptor-gamma,delta+ T cell clones. Distinct receptor-ligand interactions mediate NK-like and allospecific cytotoxicity. J Immunol. 1989 Jun 15;142(12):4161–4168. [PubMed] [Google Scholar]
  16. Mitchell M. S., Kempf R. A., Harel W., Shau H., Boswell W. D., Lind S., Bradley E. C. Effectiveness and tolerability of low-dose cyclophosphamide and low-dose intravenous interleukin-2 in disseminated melanoma [corrected]. J Clin Oncol. 1988 Mar;6(3):409–424. doi: 10.1200/JCO.1988.6.3.409. [DOI] [PubMed] [Google Scholar]
  17. Monson J. R., Ramsden C. W., Giles G. R., Brennan T. G., Guillou P. J. Lymphokine activated killer (LAK) cells in patients with gastrointestinal cancer. Gut. 1987 Nov;28(11):1420–1425. doi: 10.1136/gut.28.11.1420. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Monson J. R., Ramsden C., Guillou P. J. Decreased interleukin-2 production in patients with gastrointestinal cancer. Br J Surg. 1986 Jun;73(6):483–486. doi: 10.1002/bjs.1800730620. [DOI] [PubMed] [Google Scholar]
  19. North R. J. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med. 1982 Apr 1;155(4):1063–1074. doi: 10.1084/jem.155.4.1063. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Papa M. Z., Vetto J. T., Ettinghausen S. E., Mulé J. J., Rosenberg S. A. Effect of corticosteroid on the antitumor activity of lymphokine-activated killer cells and interleukin 2 in mice. Cancer Res. 1986 Nov;46(11):5618–5623. [PubMed] [Google Scholar]
  21. Papa M. Z., Yang J. C., Vetto J. T., Shiloni E., Eisenthal A., Rosenberg S. A. Combined effects of chemotherapy and interleukin 2 in the therapy of mice with advanced pulmonary tumors. Cancer Res. 1988 Jan 1;48(1):122–129. [PubMed] [Google Scholar]
  22. Powell C. B., Mutch D. G., Kao M. S., Collins J. L. Reduced natural cytotoxic cell activity in patients receiving cisplatin-based chemotherapy and in mice treated with cisplatin. Clin Exp Immunol. 1990 Mar;79(3):424–429. doi: 10.1111/j.1365-2249.1990.tb08106.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Rosenberg S. A., Lotze M. T., Yang J. C., Aebersold P. M., Linehan W. M., Seipp C. A., White D. E. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg. 1989 Oct;210(4):474–485. doi: 10.1097/00000658-198910000-00008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Rosenstein M., Ettinghausen S. E., Rosenberg S. A. Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. J Immunol. 1986 Sep 1;137(5):1735–1742. [PubMed] [Google Scholar]
  25. Schoof D. D., Gramolini B. A., Davidson D. L., Massaro A. F., Wilson R. E., Eberlein T. J. Adoptive immunotherapy of human cancer using low-dose recombinant interleukin 2 and lymphokine-activated killer cells. Cancer Res. 1988 Sep 1;48(17):5007–5010. [PubMed] [Google Scholar]
  26. Vetto J. T., Papa M. Z., Lotze M. T., Chang A. E., Rosenberg S. A. Reduction of toxicity of interleukin-2 and lymphokine-activated killer cells in humans by the administration of corticosteroids. J Clin Oncol. 1987 Mar;5(3):496–503. doi: 10.1200/JCO.1987.5.3.496. [DOI] [PubMed] [Google Scholar]
  27. West W. H., Tauer K. W., Yannelli J. R., Marshall G. D., Orr D. W., Thurman G. B., Oldham R. K. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med. 1987 Apr 9;316(15):898–905. doi: 10.1056/NEJM198704093161502. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES